Ixovex-1
Head and Neck Cancer
Psivac LtdPhase 1/2Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 73/ 100
Competitive context
141 Active assets in the Head and Neck Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
NEPENTHE Instituto Nacional de Cancer, Brazil | Phase 4 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II ImmunityBio, Inc. | Phase 3 | BB |
LIDOCAINE Instituto Nacional de Cancer, Brazil | Phase 3 | BB |
Carboplatin Rapa Therapeutics LLC | Phase 3 | BB |
FILGRASTIM University of Colorado, Denver | Phase 2 | BB |
View all 50 →
Same molecule, other indications
Ixovex-1 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →